Newly appointed Zealand Pharma CEO says commercial organization was too expensive

Going forward, Zealand Pharma’s revenue will come from strategic partnerships, which is why the company is significantly reducing its commercial unit and workforce in the US. It’s too expensive to have a commercial department with few products on the market, says Adam Steensberg, the company’s new CEO.

Photo: Zealand Pharma / PR

Having spent a lot of funds the past few years on building up an commercial organization in the US, biotech company Zealand Pharma has decided to change lanes completely.

As a part of a larger restructuring plan announced on Wednesday, the company will now pursue strategic partnerships when it comes to bringing current and future products to patients.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs